NVO's First Oral Obesity Pill Approval: What Does it Mean for Lilly?

Key Takeaways NVO won FDA approval for oral Wegovy, the first GLP-1 obesity pill in the U.S.LLY has filed an NDA for its oral GLP-1 orforglipron.Lilly data show orforglipron helped patients maintain weight loss after switching from Wegovy or Zepbound.Earlier this week, the FDA approved Eli Lilly and Company’s (LLY) rival Novo Nordisk’s (NVO) oral version of the obesity drug Wegovy (semaglutide). Wegovy is the first oral GLP-1 drug to be approved in the United States, ushering in a new era of obesity treatme ...